|BioMarin||PEG-PAL (formerly Phenylase)||Metabolism - phenylketonuria (PKU)||PEGylated recombinant phenylalanine ammonia lyase to reduce levels of plasma phenylalanine. IND filed|
|Biocompatibles International||CellBeads||CNS - stroke||Stem cell product given to patients immediately after haemorrhagic stroke|
|LifeCycle Pharma||LCP-Siro (sirolimus/ rapamycin)||Immune - prevention of organ rejection||Sirolimus or rapamycin is an imunosuppressant (marketed by Wyeth as Rapamune). It binds to FK-binding protein 12 (FKBP12) and then to mammalian target of rapamycin (mTOR) complex 1. This limits the response to interleukin-2 (IL-2) and therefore blocks activation of T and B cells. Product is new formulation to try and achieve increased bioavailability and reduced dosing.|
|Rigel / Pfizer||R343||Allergic asthma||IgE receptor inhibition in respiratory tract mast cells by blocking activation of syk kinase|
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.